防水台紧身裙美女:请问在深圳或是在北京，那家医院能有效治疗Remicade for Psoriatic arthritis此疾病的？

Remicade
　　是种药的牌子吧
　　Psoriatic arthritis
　　是关节病性银屑病

　　为银屑病病人同时伴发关节病，病情轻重不一，轻者只侵犯指、趾末端小关节，重者侵犯脊柱等大关节。 诊断要点：1.多数为慢性银屑病病人，少数病人初发银屑病同时侵犯关节。2.最常侵犯指、趾末节小关节; 关节轻度肿胀，疼痛不适。重症病人可侵犯手指、手腕关节、膝关节，久之关节畸形、弯曲，丧失功能。当发生银屑病性脊柱炎时，脊柱强直，活动受限。3.关节病型银屑病病人约80％病人指、趾甲有混浊、肥厚、变形。4.X线检查有骨、关节破坏改变。 5. 类风湿因子阴性。 治疗要点：1.服用阿斯匹林与非甾体类抗炎药。2.内服皮质类固醇激素，但长期用药有副作用。3.金制剂。4.物理治疗。
　　Remicade

　　史上第一支抗类风湿性关节炎发炎因子的药物

　　(FDA)美国食品药物管理局 2002年2月批准Remicade的上市。这是史上第一支抗类风湿性关节炎发病因子的药物，也有助于控制类风湿性关节炎发病的疼痛或僵硬病症。
　　根据FDA核准的处方用法, REMICADE与methotrexate可以有效阻止类风湿性关节炎患者所遭受的关节部位的损坏, 主要是关节的损伤和关节腔的狭窄.
　　临床试验实验的结果显示, 这两者药物的合并使用,不但对关节病变有良好的控制, 同时病患的疼痛、关节僵硬等状况，也获得明显的改善。

　　药名: Remicade
　　有效成分：抗甲型肿瘤坏死因子(TNFa)的单克隆抗体

　　炎性肠症(Crohn氏病),类风湿性关节炎

　　制药公司: Centocor

　　批准日期：1998年8月24日

　　用药途径：静脉注射

　　用药剂量：

　　Crohn氏病: 每公斤体重5毫克，一次静脉注射。类风湿性关节炎: 每公斤体重3毫克，首次、两周后、六周后、以及以后每八周一次静脉注射。

　　作用机理：

　　Crohn氏病主要累及小肠的后部(空肠)和结肠，也可累及肠道的任何一个部位。肠道内壁慢性炎症，主要症状包括慢性长期腹泻, 痉挛性腹痛、食欲不振和体重减少。

　　Remicade能与TNFa结合并中和TNFa的生理活性。Remicade还能够杀死合成TNFa的细胞。后者是Remicade具有强有效的抑制TNFa的作用机理。

　　因为TNFa在Crohn氏病和类风湿性关节炎中是引起和维持炎症反应的主要因素，Remicade对两种疾病的治疗作用都非常显著。被美国食品药物局(FDA)先后批准应用。

　　副作用：

　　在小病人中有轻度的上呼吸道感染、头疼和恶心等

　　Drug Name: Remicade
　　Company: Centocor
　　Approval Status: Approved February 2002
　　Treatment for: Rheumatoid arthritis

　　General Information
　　Remicade, administered through intravenous infusion, has been approved for improvement in physical function for individuals suffering from rheumatoid arthritis (RA). This recent approval is in addition to previous approvals for inhibiting the progression of structural damage and for reducing signs and symptoms of RA. The drug indicated for the treatment of Crohn's disease as well and is the only biologic drug approved for these two conditions. Remicade is also the first drug approved for this most recent indication. For RA treatment, Remicade is to be used in combination with methotrexate, a standard treatment for RA. The combination treatment is given six to eight times per year.

　　RA is a debilitating, chronic disease that affects more than two million Americans. This autoimmune disease causes the body's immune system to attack multiple joints, leading to pain, swelling and eventually to irreversile joint damage.

　　Clinical Results
　　The approval of Remicade for improvement in physical function compromised by RA is supported by a two year double-blind, placebo-controlled study that evaluated changes in physical function due to treatment with Remicade and methotrexate, compared to methotrexate alone. The primary endpoint of the trials, which included 428 subjects, was the changes in physical function and disability from baseline to study end.

　　Those who received Remicade and methotrexate experienced statistically significant improvement compared to those adminstered only methotrexate. Improvements were evident after 54 weeks of treatment and were sustained through out the entire 102 weeks.

　　Side Effects
　　Adverse events associated with the use of Remicade may include (but are not limited to) the following:

　　Upper respiratory infection
　　Cough
　　Sinusitis
　　Headache
　　Rash
　　Abdominal pain

　　Mechanism of Action
　　Remicade (infliximab) is a chimeric monoclonal antibody that targets and binds to tumor necrosis factor alpha (TNF-a). TNF-a is a key factor in regulating the inflammation in RA. By inactivating TNF-a, the inflammatory process is significantly diminished from the start.